Composite preparation comprising lercanidipine hydrochloride and valsartan and preparation method thereof

A technology for lercanidipine hydrochloride and lerca hydrochloride, which is applied in the directions of medical preparations containing active ingredients, pill delivery, and drug combinations, can solve problems such as side effects, and achieve the effects of reducing side effects and increasing dissolution rate.

Active Publication Date: 2017-12-12
LG CHEM LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, excessively increased doses may cause side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite preparation comprising lercanidipine hydrochloride and valsartan and preparation method thereof
  • Composite preparation comprising lercanidipine hydrochloride and valsartan and preparation method thereof
  • Composite preparation comprising lercanidipine hydrochloride and valsartan and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-4

[0053] Examples 1-4: Preparation of isolated particles

[0054] [Table 1]

[0055]

[0056] The lercanidipine hydrochloride granules and valsartan granules having the above composition were wet granulated with distilled water, dried and ground into 25 meshes. The two granules are mixed and compressed into a composite tablet, which is then film-coated. Selling Colorcon as PVP II was used as a film coating material, and film coating was performed in the same manner in all of the following Examples and Comparative Examples. The mixture was mixed for 5 minutes or longer to fully wet the super-integrating agent added during wet granulation. Such intensive mixing time increases the porosity of the granules, aids disintegration time to prevent gelling. In the examples below, wet granulation was performed as described above.

Embodiment 5-8

[0057] Embodiment 5-8: Preparation of composite bilayer tablet

[0058] [Table 2]

[0059]

[0060] The lercanidipine hydrochloride granules and valsartan granules having the above composition were wet granulated with distilled water, dried and ground into 25 meshes. The two sets of granules were compressed into a bilayer solid form, whereby the bilayer solid form was film coated.

Embodiment 9-12

[0061] Embodiment 9-12: Preparation of composite three-layer tablet

[0062] [table 3]

[0063]

[0064] The lercanidipine hydrochloride granules and valsartan granules having the above composition were wet granulated with distilled water, dried and ground into 25 meshes. Valsartan granules were added to make the first tablet portion, a barrier layer was added to make the second tablet portion, and lercanidipine hydrochloride granules were added to make the third tablet portion. Composite three-layer tablets are obtained and film-coated.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition containing lercanidipine hydrochloride and valsartan as active components and a preparation method thereof. The pharmaceutical composition comprising lercanidipine hydrochloride and valsartan of the present invention has excellent effects on preventing and treating cardiovascular diseases and their concurrent diseases, and reduces the side effects of each component. Furthermore, the composition of the present invention comprises lercanidipine hydrochloride and valsartan in isolated form to increase the dissolution rate of both components and reduce side effects.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing lercanidipine hydrochloride and valsartan as active components and a preparation method thereof. Background technique [0002] Hypertension is one of the most common cardiovascular diseases. Persistent high blood pressure damages blood vessels in the kidneys, heart, and brain, which increases the incidence of kidney failure, coronary heart disease, heart failure, and stroke. Hypertension is divided into two types, i.e. essential or primary hypertension and secondary hypertension. The cause of essential hypertension is unknown and occurs without a specific underlying condition. Most (95%) hypertensive patients, especially those over 40 years old, belong to this type. Although no cause of essential hypertension has been found because there is no underlying disease, the problem may lie in genetics, a diet that consumes salty foods, obesity, advanced age, stress, and alcohol and tobacco us...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4422A61K31/41A61K9/16A61P9/00
CPCA61K9/1635A61K9/1652A61K9/2027A61K9/2054A61K9/209A61K9/2095A61K31/41A61K31/4422A61K9/5084A61P9/00A61P9/12A61K2300/00A61K9/16
Inventor 丁荣识朴秀娥金利宣金成一全宰贤金烔煃金由璘朴熙东朴圣在李承学金周铉郑珉英
Owner LG CHEM LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap